Author:
Kazemian Kakhki Mahla,Mirzavi Farshad,Jalili-Nik Mohammad,Einafshar Elham,Nadi Yazdi Hanieh,Soukhtanloo Mohammad
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Alifieris, C., & Trafalis, D. T. (2015). Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & Therapeutics, 152, 63–82.
2. Eidizade, F., Soukhtanloo, M., Zhiani, R., Mehrzad, J., & Mirzavi, F. (2023). Inhibition of glioblastoma proliferation, invasion, and migration by Urolithin B through inducing G0/G1 arrest and targeting MMP-2/-9 expression and activity. Biofactors, 49, 379–389.
3. Awasthi, R., Roseblade, A., Hansbro, P. M., Rathbone, M. J., Dua, K., & Bebawy, M. (2018). Nanoparticles in cancer treatment: opportunities and obstacles. Current Drug Targets, 19, 1696–1709.
4. Zhao, P.-H., Wei, Z., Wang, L.-H., Pang, C., Zhang, H.-R., Wang, J., et al. (2021). Delivery of temozolomide using PEGylated graphene oxide as a nanocarrier. Materials Express, 11, 189–195.
5. Wang, B., Guo, H., Xu, H., Chen, Y., Zhao, G., & Yu, H. (2022). The role of graphene oxide nanocarriers in treating gliomas. Frontiers in Oncology, 12, 176.